One drop of blood is all it takes
to test for any biomarker at home

DEMOCRATIZING

CLINICAL DATA

Investors SARS-CoV-2

INVESTORS

About

The company has a product for blood biomarker testing. Customers demand this type of product and several contacts have already been made with vital institutions in Denmark. Sales for professional use are commenced in 2020.

Read more

Investors

Here you will find the share information for Qlife Holding AB. Our press releases and financial quarterly reports, our annual reports, calendar and information about our corporate governance work. Qlife Holding AB aims for a fast and transparent accounting to shareholders and the financial market.

The company is listed on Nasdaq, First North Growth Market, Stockholm as from March 2, 2020

Continue

Egoo.health

The Egoo product is a platform for accurate bio-marker testing. At a low cost and with equipment easy to use, it measures and analyses the patient’s blood. The patient can do the testing at home themselves. Read more on our product page.

Egoo.health

Contact

If you have any questions about us or our ongoing IPO feel free to send us a message.

 

 

You agree by using this feature that your information is handled in accordance with applicable GDPR legislation.
10 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Film - EGOO HEALTH EXPLAINED

In less than four minutes, CEO Thomas Warthoe explains what Egoo Health is all about, how it works and why it makes a difference for ordinary people, medical staff and health institutions. 

Read more about us

NEWS/PRESS

2020-05-20
Bulletin from the Annual General Meeting in Qlife Holding AB on May 20th, 2020

Resolution on adoption of accounts and allocation of the company’s result

2020-05-20
Qlife Holding AB, Interim Report January – March 2020

FINANCIAL SUMMARY FIRST QUARTER 2020

2020-05-12
Qlife has entered a first strategically important sales agreement for their COVID-19 test

The parties have agreed a testing plan for all players, judges and club staff for Covid-19 in the professional leagues (3F SuperLiga and NordicBet Liga).

2020-04-22
Qlife enters agreement with Nordsjællands Hospital to start validation of COVID-19 test

Qlife announces that it has entered into a research agreement with Nordsjællands Hospital (NOH), to continue the validation of the Egoo Sars-CoV-2 virus test.

2020-04-16
Notice of annual shareholders’ meeting in Qlife Holding AB

Information regarding the coronavirus

2020-04-03
Qlife updates on process for COVID-19 test

Due to increased requests for information on route to market for Qlife’s COVID-19 test the company is updating the following:

2020-03-31
Qlife to expand the Egoo.Health platform with COVID-19 test through licence deal

Qlife announces that it has closed a license and supply agreement with Aidian Oy to access and incorporate their patented SIBA® Technology into the Egoo.Health platform.

2020-03-13
Corona virus, COVID-19, has limited impact on Qlife Holding AB

Qlife went public on March 2 with a clear strategy for the next year, that strategy is still being followed and we do not see any large obstacles to it due to the Corona virus outbreak.

2020-03-02
Qlife commences trading on Nasdaq First North Growth Market

Qlife Holding AB announces that the trading in the company’s shares (short name: QLIFE) will commence today on the Nasdaq First North Growth Market in Stockholm.